Cover Image
市場調查報告書

蛋白質療法的全球市場:各產品 (單株抗體,胰島素,融合蛋白品質,促血紅細胞生長素,干擾素,卵巢刺激荷爾蒙)、用途 - 市場機會分析與產業預測

Protein Therapeutics Market by Product (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, and Follicle Stimulating Hormone) and Application - Global Opportunity Analysis & Industry Forecast, 2017-2023

出版商 Allied Market Research 商品編碼 586571
出版日期 內容資訊 英文 211 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
蛋白質療法的全球市場:各產品 (單株抗體,胰島素,融合蛋白品質,促血紅細胞生長素,干擾素,卵巢刺激荷爾蒙)、用途 - 市場機會分析與產業預測 Protein Therapeutics Market by Product (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, and Follicle Stimulating Hormone) and Application - Global Opportunity Analysis & Industry Forecast, 2017-2023
出版日期: 2017年11月01日 內容資訊: 英文 211 Pages
簡介

本報告提供全球蛋白質療法的市場相關分析,產品概要和市場基本結構,主要的推動及阻礙市場的要素,市場規模預測 (今後7年份),各產品、各用途 (各疾病)、各地區的詳細趨勢,主要企業簡介等調查。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 分析的要點
    • 主要的投資財源
    • 主要的成功策略
  • 波特的五力分析
  • 政府的法規
  • 前幾名企業的定位
  • 市場動態
    • 市場的推動要素
    • 市場的阻礙要素
    • 市場機會

第4章 蛋白質療法市場:各產品

  • 概要
    • 市場規模與其預測
  • 單株抗體
    • 市場主要趨勢
    • 成長要素,市場機會
    • 市場規模與其預測
  • 胰島素
  • 融合蛋白品質
  • 促血紅細胞生長素
  • 干擾素
  • 人體生長荷爾蒙
  • 卵巢刺激荷爾蒙

第5章 蛋白質療法市場:各用途

  • 概要
  • 代謝異常
    • 市場規模與其預測
  • 免疫疾病
  • 血液疾病
  • 癌症
  • 荷爾蒙障礙
  • 遺傳基因疾病
  • 其他

第6章 蛋白質療法市場:各地區

  • 概要
  • 北美市場 (美國,加拿大,墨西哥)
    • 市場主要趨勢
    • 市場規模與其預測:各國
    • 市場規模與其預測:各產品
    • 市場規模與其預測:各用途
  • 歐洲市場 (德國,法國,英國,義大利,西班牙等)
  • 亞太地區市場 (日本,中國,澳洲,印度,韓國,台灣等)
  • 南美、中東、非洲 (LAMEA:巴西,沙烏地阿拉伯,南非等)

第7章 企業簡介

  • ABBOTT LABORATORIES
    • 企業概要
    • 主要資料
    • 事業部門
    • 產品系列
    • 業績
    • 主要策略、趨勢
  • AMGEN, INC.
  • BAXTER INTERNATIONAL INC.
  • ELI LILLY AND COMPANY
  • F. HOFFMANN-LA ROCHE AG
  • JOHNSON & JOHNSON
  • MERCK & CO., INC.
  • NOVO NORDISK A/S
  • PFIZER INC.
  • SANOFI
目錄
Product Code: LI 1760

Title:
Protein Therapeutics Market by Product (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, and Follicle Stimulating Hormone) and Application (Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to reach $217,591 million by 2023, registering a CAGR of 6.5% from 2017 to 2023.

In principle, protein therapy is similar to gene therapy, and involves protein delivery in specific amounts to the body to aid in precise functioning of different glands and other organs in the body. Protein therapeutics play a pivotal role in treatment of an array of different diseases such as diabetes, lymphoma, hepatitis, and others.

Surge in prevalence of chronic diseases and rise in development of plasma-derived therapies supplement the market growth. However, stringent government regulations towards protein therapeutics and high treatment costs per patient impede the market growth. Conversely, increase in novel indications for known protein therapeutics and untapped emerging markets offer lucrative opportunities for the market players.

The protein therapeutics market is segmented based product, application, and geography. By product, the market is divided into monoclonal antibodies, insulin, fusion protein, erythropoietin, interferon, human growth hormone, and follicle stimulating hormone. On the basis of application, it is classified into metabolic disorders, immunologic disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, and others. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The report provides extensive competitive analysis and profiles of key market players, such as Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc., and Sanofi. Other players (profiles not included in the report) in the value chain analysis include, Biogen, Inc., CSL Behring, and Genentech, Inc.

KEY MARKET BENEFITS:

  • The study provides an in-depth analysis of the global protein therapeutics market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • The report presents quantitative analysis of the market from 2017 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market based on application assists in understanding the trends in the industry.
  • Key market players along with their strategies are thoroughly analyzed to understand the competitive outlook of the industry.

KEY MARKET SEGMENTS:

By Product

  • Monoclonal Antibodies
  • Insulin
  • Fusion Protein
  • Erythropoietin
  • Interferon
  • Human Growth Hormone
  • Follicle Stimulating Hormone

By Application

  • Metabolic Disorders
  • Immunologic Disorders
  • Hematological Disorders
  • Cancer
  • Hormonal Disorders
  • Genetic Disorders
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Taiwan
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. KEY BENEFITS
  • 1.3. KEY MARKET SEGMENTS
  • 1.4. RESEARCH METHODOLOGY
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO PERSPECTIVE

CHAPTER 3: MARKET OVERVIEW

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. KEY FINDINGS
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. PORTERS FIVE FORCE ANALYSIS
  • 3.4. GOVERNMENT REGULATIONS
  • 3.5. TOP PLAYER POSITIONING
  • 3.6. MARKET DYNAMICS
    • 3.6.1. Drivers
      • 3.6.1.1. Rise in healthcare expenditure
      • 3.6.1.2. Increase in R&D investments
      • 3.6.1.3. Growth in proteomics research
      • 3.6.1.4. Rise in incidence of chronic diseases
    • 3.6.2. Restraints
      • 3.6.2.1. High production costs
    • 3.6.3. Opportunities
      • 3.6.3.1. Training for professionals
      • 3.6.3.2. Greater potency with reduced costs and increasing affordability
      • 3.6.3.3. Untapped emerging markets

CHAPTER 4: PROTEIN THERAPEUTICS MARKET, BY PRODUCT

  • 4.1. OVERVIEW
    • 4.1.1. Market size and forecast
  • 4.2. MONOCLONAL ANTIBODY
    • 4.2.1. Key market trends
    • 4.2.2. Key growth factors and opportunities
    • 4.2.3. Market size and forecast
  • 4.3. INSULIN
    • 4.3.1. Key market trends
    • 4.3.2. Key growth factors and opportunities
    • 4.3.3. Market size and forecast
  • 4.4. FUSION PROTEIN
    • 4.4.1. Key market trends
    • 4.4.2. Key growth factors and opportunities
    • 4.4.3. Market size and forecast
  • 4.5. ERYTHROPOIETIN
    • 4.5.1. Key market trends
    • 4.5.2. Key growth factors and opportunities
    • 4.5.3. Market size and forecast
  • 4.6. INTERFERON
    • 4.6.1. Key market trends
    • 4.6.2. Key growth factors and opportunities
    • 4.6.3. Market size and forecast
  • 4.7. HUMAN GROWTH HORMONE
    • 4.7.1. Key market trends
    • 4.7.2. Key growth factors and opportunities
    • 4.7.3. Market size and forecast
  • 4.8. FOLLICLE-STIMULATING HORMONE
    • 4.8.1. Key market trends
    • 4.8.2. Key growth factors and opportunities
    • 4.8.3. Market size and forecast

CHAPTER 5: PROTEIN THERAPEUTICS MARKET, BY APPLICATION

  • 5.1. OVERVIEW
    • 5.1.1. Market size and forecast
  • 5.2. METABOLIC DISORDERS
    • 5.2.1. Market size and forecast
  • 5.3. IMMUNOLOGICAL DISORDERS
    • 5.3.1. Market size and forecast
  • 5.4. HEMATOLOGICAL DISORDERS
    • 5.4.1. Market size and forecast
  • 5.5. CANCER
    • 5.5.1. Market size and forecast
  • 5.6. HORMONAL DISORDERS
    • 5.6.1. Market size and forecast
  • 5.7. GENETIC DISORDERS
    • 5.7.1. Market size and forecast
  • 5.8. OTHERS
    • 5.8.1. Market size and forecast

CHAPTER 6: PROTEIN THERAPEUTICS MARKET, BY GEOGRAPHY

  • 6.1. OVERVIEW
    • 6.1.1. Market size and forecast, by country
  • 6.2. NORTH AMERICA
    • 6.2.1. Key market trends
    • 6.2.2. Key growth factors and opportunities
    • 6.2.3. Market size and forecast, by country
    • 6.2.4. Market size and forecast, by product
    • 6.2.5. Market size and forecast, by application
      • 6.2.5.1. U.S. market size and forecast, by product
      • 6.2.5.2. U.S. market size and forecast, by application
      • 6.2.5.3. Canada market size and forecast, by product
      • 6.2.5.4. Canada market size and forecast, by application
      • 6.2.5.5. Mexico market size and forecast, by product
      • 6.2.5.6. Mexico market size and forecast, by application
  • 6.3. EUROPE
    • 6.3.1. Key market trends
    • 6.3.2. Key growth factors and opportunities
    • 6.3.3. Market size and forecast, by country
    • 6.3.4. Market size and forecast, by product
    • 6.3.5. Market size and forecast, by application
      • 6.3.5.1. Germany market size and forecast, by product
      • 6.3.5.2. Germany market size and forecast, by application
      • 6.3.5.3. France market size and forecast, by product
      • 6.3.5.4. France market size and forecast, by application
      • 6.3.5.5. UK market size and forecast, by product
      • 6.3.5.6. UK market size and forecast, by application
      • 6.3.5.7. Italy market size and forecast, by product
      • 6.3.5.8. Italy market size and forecast, by application
      • 6.3.5.9. Spain market size and forecast, by product
      • 6.3.5.10. Spain market size and forecast, by application
      • 6.3.5.11. Rest of Europe market size and forecast, by product
      • 6.3.5.12. Rest of Europe market size and forecast, by application
  • 6.4. ASIA-PACIFIC
    • 6.4.1. Key market trends
    • 6.4.2. Key growth factors and opportunities
    • 6.4.3. Market size and forecast, by country
    • 6.4.4. Market size and forecast, by product
    • 6.4.5. Market size and forecast, by application
      • 6.4.5.1. Japan market size and forecast, by product
      • 6.4.5.2. Japan market size and forecast, by application
      • 6.4.5.3. China market size and forecast, by product
      • 6.4.5.4. China market size and forecast, by application
      • 6.4.5.5. Australia market size and forecast, by product
      • 6.4.5.6. Australia market size and forecast, by application
      • 6.4.5.7. India market size and forecast, by product
      • 6.4.5.8. India market size and forecast, by application
      • 6.4.5.9. South Korea market size and forecast, by product
      • 6.4.5.10. South Korea market size and forecast, by application
      • 6.4.5.11. Taiwan market size and forecast, by product
      • 6.4.5.12. Taiwan market size and forecast, by application
      • 6.4.5.13. Rest of Asia-Pacific market size and forecast, by product
      • 6.4.5.14. Rest of Asia-Pacific market size and forecast, by application
  • 6.5. LAMEA
    • 6.5.1. Key market trends
    • 6.5.2. Key growth factors and opportunities
    • 6.5.3. Market size and forecast, by country
    • 6.5.4. Market size and forecast, by product
    • 6.5.5. Market size and forecast, by application
      • 6.5.5.1. Brazil market size and forecast, by product
      • 6.5.5.2. Brazil market size and forecast, by application
      • 6.5.5.3. Saudi Arabia market size and forecast, by product
      • 6.5.5.4. Saudi Arabia market size and forecast, by application
      • 6.5.5.5. South Africa market size and forecast, by product
      • 6.5.5.6. South Africa market size and forecast, by application
      • 6.5.5.7. Rest of LAMEA market size and forecast, by product
      • 6.5.5.8. Rest of LAMEA market size and forecast, by application

CHAPTER 7: COMPANY PROFILES

  • 7.1. ABBOTT LABORATORIES
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Operating business segments
    • 7.1.4. Product portfolio
    • 7.1.5. Business performance
    • 7.1.6. Key strategic moves and developments
  • 7.2. AMGEN, INC.
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
    • 7.2.3. Operating business segments
    • 7.2.4. Product portfolio
    • 7.2.5. Business performance
    • 7.2.6. Key strategic moves and developments
  • 7.3. BAXTER INTERNATIONAL INC.
    • 7.3.1. Company overview
    • 7.3.2. Company snapshot
    • 7.3.3. Operating business segments
    • 7.3.4. Product portfolio
    • 7.3.5. Business performance
    • 7.3.6. Key strategic moves and developments
  • 7.4. ELI LILLY AND COMPANY
    • 7.4.1. Company overview
    • 7.4.2. Company snapshot
    • 7.4.3. Operating business segments
    • 7.4.4. Product portfolio
    • 7.4.5. Business performance
    • 7.4.6. Key strategic moves and developments
  • 7.5. F. HOFFMANN-LA ROCHE AG
    • 7.5.1. Company overview
    • 7.5.2. Company snapshot
    • 7.5.3. Operating business segments
    • 7.5.4. Product portfolio
    • 7.5.5. Business performance
    • 7.5.6. Key strategic moves and developments
  • 7.6. JOHNSON & JOHNSON
    • 7.6.1. Company overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Operating business segments
    • 7.6.4. Product portfolio
    • 7.6.5. Business performance
    • 7.6.6. Key strategic moves and developments
  • 7.7. MERCK & CO., INC.
    • 7.7.1. Company overview
    • 7.7.2. Company snapshot
    • 7.7.3. Operating business segments
    • 7.7.4. Product portfolio
    • 7.7.5. Business performance
    • 7.7.6. Key strategic moves and developments
  • 7.8. NOVO NORDISK A/S
    • 7.8.1. Company overview
    • 7.8.2. Company snapshot
    • 7.8.3. Operating business segments
    • 7.8.4. Product portfolio
    • 7.8.5. Business performance
    • 7.8.6. Key strategic moves and developments
  • 7.9. PFIZER INC.
    • 7.9.1. Company overview
    • 7.9.2. Company snapshot
    • 7.9.3. Operating business segments
    • 7.9.4. Product portfolio
    • 7.9.5. Business performance
    • 7.9.6. Key strategic moves and developments
  • 7.10. SANOFI
    • 7.10.1. Company overview
    • 7.10.2. Company snapshot
    • 7.10.3. Operating business segments
    • 7.10.4. Product portfolio
    • 7.10.5. Business performance
    • 7.10.6. Key strategic moves and developments

List of Tables

  • TABLE 1. KEY MONOCLONAL ANTIBODIES AND THEIR MANUFACTURERS
  • TABLE 2. PROTEIN THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 3. KEY INSULIN PRODUCTS AND THEIR MANUFACTURERS
  • TABLE 4. PROTEIN THERAPEUTICS MARKET FOR INSULIN, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 5. PROTEIN THERAPEUTICS MARKET FOR FUSION PROTEIN, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 6. PROTEIN THERAPEUTICS MARKET FOR ERYTHROPOIETIN, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 7. PROTEIN THERAPEUTICS MARKET FOR INTERFERON, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 8. PROTEIN THERAPEUTICS MARKET FOR HUMAN GROWTH HORMONE, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 9. PROTEIN THERAPEUTICS MARKET FOR FOLLICLE-STIMULATING HORMONE, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 10. GLOBAL PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 11. SOME OF THE THERAPEUTIC PROTEINS USED TO TREAT METABOLIC DISORDERS
  • TABLE 12. PROTEIN THERAPEUTICS MARKET FOR METABOLIC DISORDERS, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 13. SOME OF THE THERAPEUTIC PROTEINS USED TO TREAT IMMUNOLOGICAL DISORDERS
  • TABLE 14. PROTEIN THERAPEUTICS MARKET FOR IMMUNOLOGIC DISORDERS, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 15. SOME OF THE THERAPEUTIC PROTEINS USED TO TREAT HEMATOLOGICAL DISORDERS
  • TABLE 16. PROTEIN THERAPEUTICS MARKET FOR HEMATOLOGICAL DISORDERS, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 17. SOME OF THE THERAPEUTIC PROTEINS USED TO TREAT CANCER
  • TABLE 18. PROTEIN THERAPEUTICS MARKET FOR CANCER, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 19. SOME OF THE THERAPEUTIC PROTEINS USED TO TREAT HORMONAL DISORDERS
  • TABLE 20. PROTEIN THERAPEUTICS MARKET FOR HORMONAL DISORDERS, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 21. SOME OF THE THERAPEUTIC PROTEINS USED TO TREAT GENETIC DISORDERS
  • TABLE 22. PROTEIN THERAPEUTICS MARKET FOR GENETIC DISORDERS, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 23. SOME OF THE THERAPEUTIC PROTEINS USED TO TREAT OTHER TYPES OF DISORDERS
  • TABLE 24. PROTEIN THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 25. PROTEIN THERAPEUTICS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 26. NORTH AMERICA PROTEIN THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 27. NORTH AMERICA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 28. NORTH AMERICA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 29. U.S. PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 30. U.S. PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 31. CANADA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 32. CANADA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 33. MEXICO PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 34. MEXICO PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 35. EUROPE PROTEIN THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 36. EUROPE PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 37. EUROPE PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 38. GERMANY PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 39. GERMANY PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 40. FRANCE PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 41. FRANCE PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 42. UK PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 43. UK PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 44. ITALY PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 45. ITALY PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 46. SPAIN PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 47. SPAIN PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 48. REST OF EUROPE PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 49. REST OF EUROPE PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 50. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 51. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 52. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 53. JAPAN PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 54. JAPAN PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 55. CHINA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 56. CHINA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 57. AUSTRALIA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 58. AUSTRALIA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 59. INDIA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 60. INDIA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 61. SOUTH KOREA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 62. SOUTH KOREA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 63. TAIWAN PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 64. TAIWAN PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 65. REST OF ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 66. REST OF ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 67. LAMEA PROTEIN THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 68. LAMEA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 69. LAMEA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 70. BRAZIL PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 71. BRAZIL PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 72. SAUDI ARABIA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 73. SAUDI ARABIA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 74. SOUTH AFRICA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 75. SOUTH AFRICA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 76. REST OF LAMEA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • TABLE 77. REST OF LAMEA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 78. ABBOTT: COMPANY SNAPSHOT
  • TABLE 79. ABBOTT: OPERATING SEGMENTS
  • TABLE 80. ABBOTT: PRODUCT PORTFOLIO
  • TABLE 81. AMGEN: COMPANY SNAPSHOT
  • TABLE 82. AMGEN: OPERATING SEGMENTS
  • TABLE 83. AMGEN: PRODUCT PORTFOLIO
  • TABLE 84. BAXTER: COMPANY SNAPSHOT
  • TABLE 85. BAXTER: OPERATING SEGMENTS
  • TABLE 86. BAXTER: PRODUCT PORTFOLIO
  • TABLE 87. LILLY: COMPANY SNAPSHOT
  • TABLE 88. LILLY: OPERATING SEGMENTS
  • TABLE 89. LILLY: OPERATING SEGMENTS
  • TABLE 90. ROCHE: COMPANY SNAPSHOT
  • TABLE 91. ROCHE: OPERATING SEGMENT
  • TABLE 92. ROCHE: PRODUCT PORTFOLIO
  • TABLE 93. J&J: COMPANY SNAPSHOT
  • TABLE 94. J&J: OPERATING SEGMENTS
  • TABLE 95. J&J: PRODUCT PORTFOLIO
  • TABLE 96. MERCK: COMPANY SNAPSHOT
  • TABLE 97. MERCK: OPERATING SEGMENTS
  • TABLE 98. MERCK: PRODUCT PORTFOLIO
  • TABLE 99. NOVO NORDISK: COMPANY SNAPSHOT
  • TABLE 100. NOVO NORDISK: OPERATING SEGMENTS
  • TABLE 101. NOVO NORDISK: PRODUCT PORTFOLIO
  • TABLE 102. PFIZER: COMPANY SNAPSHOT
  • TABLE 103. PFIZER: OPERATING SEGMENTS
  • TABLE 104. PFIZER: PRODUCT PORTFOLIO
  • TABLE 105. SANOFI: COMPANY SNAPSHOT
  • TABLE 106. SANOFI: OPERATING SEGMENTS
  • TABLE 107. SANOFI: PRODUCT PORTFOLIO

List of Figures

  • FIGURE 1. TOP INVESTMENT POCKETS
  • FIGURE 2. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2017)
  • FIGURE 3. TOP WINNING STRATEGIES: NATURE AND TYPE
  • FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 5. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 6. MODERATE THREAT OF SUBSTITUTION
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANT
  • FIGURE 8. MODERATE COMPETITIVE RIVALRY
  • FIGURE 9. GLOBAL PROTEIN THERAPEUTICS MARKET: TOP PLAYER POSITIONING
  • FIGURE 10. PROTEIN THERAPEUTICS MARKET: PRODUCT SEGMENTATION
  • FIGURE 11. GLOBAL PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
  • FIGURE 12. PROTEIN THERAPEUTICS MARKET: APPLICATION SEGMENTATION
  • FIGURE 13. ABBOTT: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 14. ABBOTT: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 15. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 16. AMGEN: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 17. AMGEN: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 18. BAXTER: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 19. BAXTER: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 20. BAXTER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 21. LILLY: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 22. LILLY: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 23. LILLY: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 24. ROCHE: REVENUE, 2014-2016 ($MILLION)
  • FIGURE 25. ROCHE: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 26. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 27. J&J: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 28. J&J: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 29. J&J: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 30. MERCK: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 31. MERCK: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 32. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 33. NOVO NORDISK: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 34. NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 35. NOVO NORDISK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 36. PFIZER: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 37. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 38. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 39. SANOFI: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 40. SANOFI: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 41. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
Back to Top